Protein Overexpression: Reaching the limit
How many copies of a protein can be made before it becomes toxic to the cell?
-
Download
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Protein Overexpression: Reaching the limiteLife 7:e39804.https://doi.org/10.7554/eLife.39804 - Cite
- CommentOpen annotations (there are currently 0 annotations on this page).
- Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Spain
- Barcelona Institute of Science and Technology, Spain
- Universitat Pompeu Fabra, Spain
- Institució Catalana de Recerca i Estudis Avançats, Spain
Cells can be pictured as factories that build proteins, the molecules essential for nearly all of life’s processes. The body tightly controls production levels, because creating too many proteins – also known as protein overexpression – can be harmful to the cell. Yet, it is difficult to know how much of any given protein will be harmful, or why.
Indeed, high concentrations of enzymes and other proteins can harm cells in several ways, for example by activating or overloading specific biological pathways, disrupting regulation, or by aggregating together (Vavouri et al., 2009; Tang and Amon, 2013; Makanae et al., 2013). They can also upset the balance in protein complexes or make the different liquid phases separate in the cell (Birchler and Veitia, 2012; Bolognesi et al., 2016). Ultimately, overexpressing any protein will be destructive because it exhausts the resources of the cell to make and transport proteins (Stoebel et al., 2008). However, we did not know how much of a specific protein must be produced to cause this ‘protein burden’ and hinder cell growth.
Now, in eLife, Hisao Moriya and colleagues at the universities of Okayama, Kobe and Meiji – including Yuichi Eguchi as first author – report that many members of a group of enzymes can be overexpressed until they form 15% of the total proteins in a yeast cell (Eguchi et al., 2018). Only then do they start to cause damage because of protein burden. This matches the results of previous experiments from the same laboratory, which only focused on a single fluorescent protein that did not interfere with any components of the cell (Kintaka et al., 2016).
To discover this limit, Eguchi et al. relied on a method the lab developed in 2006. The technique involves inserting a small portion of DNA, called a plasmid, into the yeast cells. The plasmid carries two genes: the first is essential for growth, and the other codes for one of the enzymes studied. The cell increasingly needs to make new plasmids in order to grow, but this also creates more enzymes. In this ‘tug-of-war’ system, the yeast generates more and more plasmids until the expression of the enzyme of interest becomes harmful; at this point, plasmid production decreases. The number of plasmids in the cell thus reflects the quantity of protein that can be made before it turns toxic.
The experiments focused on a set of 29 glycolytic enzymes, which break down sugar in yeast. These enzymes are normally highly expressed in a cell, and their roles are well understood.
Out of the 29 proteins, three were not harmful in the experiment and could not be produced in high enough amounts to reach the burden limit. This was because the genes that encoded these enzymes contained sequences that were not optimal for protein production.
Another 19 enzymes could be expressed until they formed close to 15% of the total protein content of the cell, which suggests that protein burden is the cause of their toxicity. The fact that even large essential yeast enzymes could be produced up to this limit is unexpected, and it suggests that in many cases the toxicity created by protein overexpression does not depend on the specific characteristics of the proteins.
The cost of overexpression may come from the burden it puts on the machinery that assembles proteins in the cell, which requires particularly high levels of energy (Shah et al., 2013). Putting this apparatus under pressure could impair or slow it down; in turn, this may hinder the creation of other proteins and decrease the fitness of the cell. The other steps of protein production, such as ‘reading’ the genes, helping the protein to mature, bringing it to its right location in the cell, and degrading it, also use significant amounts of energy (Rice and McLysaght, 2017).
Seven proteins caused harm at concentrations far below the 15% limit, which means that they must damage the cell in other ways than by causing a protein burden. Eguchi et al. identified three mechanisms for this toxicity: the proteins aggregated together, they overloaded a transport system that takes them to a specific cell compartment, or the overexpressed enzymes produced too much catalytic activity (Figure 1). One might have expected this last process to drive the toxic effects of this group of proteins. Yet, killing catalytic activity in the enzymes (by introducing specific mutations) only relieved the toxicity caused by overexpression for two of the 18 proteins that were tested.
Figure 1
Different mechanisms of toxicity induced by protein overexpression.
Many enzymes involved in glycolysis such as GFP or Pgk1 do not cause any harm until they are overexpressed up to or close to the protein burden limit, which corresponds to 15% of the total proteins …
In many cases, removing one mechanism of toxicity increased the level to which an enzyme could be overexpressed, but it still did not allow expression up to the 15% limit. Proteins could therefore be damaging through a range of mechanisms, each of which gets triggered when the concentration in the cell reaches a particular level.
While the glycolytic enzymes belong to the same pathway and share extremely similar roles, their overexpression affects cell growth via diverse mechanisms. In other words, the biological role of a protein cannot be used to predict how it will harm the cell. Altogether, these results stimulate important lines of enquiry, such as looking into which of the above mechanisms damage cells when gene expression changes during disease. They also encourage further research so that we could predict at which concentration the expression of every human gene will be harmful in any tissue. And finally, they raise the question: is protein burden what has stopped increased gene expression during evolution?
References
Article and author information
Author details
Benedetta Bolognesi
Publication history
Copyright
© 2018, Bolognesi et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 22,108
- views
-
- 978
- downloads
-
- 49
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Further reading
-
- Computational and Systems Biology
Mass spectrometry imaging (MSI) is a powerful technology used to define the spatial distribution and relative abundance of metabolites across tissue cryosections. While software packages exist for pixel-by-pixel individual metabolite and limited target pairs of ratio imaging, the research community lacks an easy computing and application tool that images any metabolite abundance ratio pairs. Importantly, recognition of correlated metabolite pairs may contribute to the discovery of unanticipated molecules in shared metabolic pathways. Here, we describe the development and implementation of an untargeted R package workflow for pixel-by-pixel ratio imaging of all metabolites detected in an MSI experiment. Considering untargeted MSI studies of murine brain and embryogenesis, we demonstrate that ratio imaging minimizes systematic data variation introduced by sample handling, markedly enhances spatial image contrast, and reveals previously unrecognized metabotype-distinct tissue regions. Furthermore, ratio imaging facilitates identification of novel regional biomarkers and provides anatomical information regarding spatial distribution of metabolite-linked biochemical pathways. The algorithm described herein is applicable to any MSI dataset containing spatial information for metabolites, peptides or proteins, offering a potent hypothesis generation tool to enhance knowledge obtained from current spatial metabolite profiling technologies.
-
- Computational and Systems Biology
- Microbiology and Infectious Disease
Antimicrobial peptides (AMPs) are attractive candidates to combat antibiotic resistance for their capability to target biomembranes and restrict a wide range of pathogens. It is a daunting challenge to discover novel AMPs due to their sparse distributions in a vast peptide universe, especially for peptides that demonstrate potencies for both bacterial membranes and viral envelopes. Here, we establish a de novo AMP design framework by bridging a deep generative module and a graph-encoding activity regressor. The generative module learns hidden ‘grammars’ of AMP features and produces candidates sequentially pass antimicrobial predictor and antiviral classifiers. We discovered 16 bifunctional AMPs and experimentally validated their abilities to inhibit a spectrum of pathogens in vitro and in animal models. Notably, P076 is a highly potent bactericide with the minimal inhibitory concentration of 0.21 μM against multidrug-resistant Acinetobacter baumannii, while P002 broadly inhibits five enveloped viruses. Our study provides feasible means to uncover the sequences that simultaneously encode antimicrobial and antiviral activities, thus bolstering the function spectra of AMPs to combat a wide range of drug-resistant infections.
